Table 1.
Baseline and on-treatment characteristics of the study population.
| Variables | Overall (N = 1,042) | Patients without HCC (N = 911) | Patients with HCC (n = 131) | P-value |
|---|---|---|---|---|
| Age, y | 48.4 ± 11.7 | 47.4 ± 11.7 | 55.3 ± 8.39 | <0.001 |
| Male gender, n (%) | 701 (67.3) | 604 (66.3) | 97 (74.0) | 0.096 |
| Diabetes mellitus, n (%) | 85 (8.2) | 62 (6.81) | 23 (17.6) | <0.001 |
| HBeAg-positive, n (%) | 439 (42.1) | 380 (41.7) | 59 (45.0) | 0.476 |
| HBV DNA, log10IU/ml | 5.11 ± 1.53 | 5.12 ± 1.56 | 5.07 ± 1.28 | 0.737 |
| AVT type | 0.003 | |||
| ETV, n (%) | 937 (89.9) | 810 (88.9) | 127 (96.9) | |
| TDF, n (%) | 105 (10.1) | 101 (11.1) | 4 (3.1) | |
| ALT, IU/mL | 83.2 ± 125 | 86.1 ± 131 | 63.2 ± 65.7 | 0.002 |
| AST, IU/mL | 67.7 ± 85.5 | 68.5 ± 88.0 | 61.7 ± 65.7 | 0.287 |
| Platelet count, ×109/L | 113.0 ± 48.9 | 115.0 ± 48.3 | 98.0 ± 50.6 | <0.001 |
| Albumin, g/L | 40.2 ± 5.58 | 40.4 ± 5.58 | 38.7 ± 5.31 | <0.001 |
| Total bilirubin, μmol/L | 24.4 ± 27.1 | 23.7 ± 25.3 | 29.3 ± 36.8 | 0.094 |
| aMAP score | 57.8 ± 7.16 | 57.1 ± 7.04 | 62.6 ± 6.06 | <0.001 |
| CAMD score | 14.0 ± 2.33 | 13.7 ± 2.27 | 15.6 ± 1.98 | <0.001 |
| PAGE-B score | 15.7 ± 4.14 | 15.4 ± 4.11 | 18.1 ± 3.54 | <0.001 |
| mPAGE-B score | 11.8 ± 3.15 | 11.5 ± 3.13 | 13.8 ± 2.47 | <0.001 |
| 1-year aMAP score | 56.7 ± 7.25 | 55.9 ± 7.11 | 61.9 ± 5.98 | <0.001 |
| ΔaMAP ≥ 0, n (%) | 407 (39.1) | 348 (38.2) | 59 (45.0) | 0.151 |
Categorical variables were presented as frequency (percentage). Follow-up duration was expressed in median (interquartile range). Other continuous variables were expressed in mean ± standard deviation. ΔaMAP presented the on-treatment change in aMAP score (from 1 year of treatment to baseline).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; AVT, antiviral treatment; CI, confidence interval; ETV, entecavir; HBeAg, hepatitis B e antigen; TDF, tenofovir.